ArticleVox sanguinis2026
Studies of platelet antibodies at MacKay Memorial Hospital in Taiwan: Methods, case reviews and a possible case of post-transfusion purpura.
Article in Vox sanguinis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesPlatelet antibody screening and identification are crucial and challenging. MacKay Memorial Hospital has been dedicated to this for nearly four decades. We reviewed our experience with platelet antibody detection methods and prevalence, and presented a possible case of post-transfusion purpura caused by anti-CD36. MATERIALS AND
methodsWe analyzed platelet antibody screening results from 1988 to 2024. We used solid phase red cell adherence test (SPRCA) from 1988 to 2018 (9268 samples), and parallel SPRCA/enzyme-linked immunosorbent assay (ELISA) from 2019 to 2024 (2037 samples). Positive results are further identified through flow cytometry, monoclonal antibody immobilization of platelet antigens (MAIPA), or in-house platelet antigen panels. We also studied a possible case of post-transfusion purpura (PTP) caused by anti-CD36. A 79-year-old woman was treated with numerous platelet transfusions that were ineffective, with generalized purpura appearing a few days later following massive transfusion.
resultsFrom 1988-2018, 2800 of 9268 samples (30.2%) were positive. Six cases of neonatal alloimmune thrombocytopenia (NAITP) were identified (two anti-HPA-3a, two anti-HPA-5a, and two anti-CD36). From 2019-2024, 778 of 2037 samples (38.19%) were positive. Specific antibodies were identified in eight cases, and six of them were anti-CD36. Introduction of ELISA resulted in a 15-fold detection rate of anti-CD36 (0.02% to 0.29%), suggesting previous underestimation. In the possible PTP case, massive transfusion was started on Day 8 of hospitalization, purpura appeared on Day 15, anti-CD36 was identified on Day 21, and CD36-negative platelet transfusion was initiated on the following day. However, the patient eventually died of multiorgan failure on Day 29.
conclusionThe prevalence of anti-CD36 antibody in the Taiwanese population was previously underestimated. Clinicians should be aware that not only human platelet antigen (HPA) but CD36 should also be considered when platelet refractoriness persists despite HLA-matched transfusion, as anti-CD36 may cause serious complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.